Screen Shot 2018-03-05 at 12.10.56 PM

The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options

http://academiccme.com/wp-content/uploads/2018/02/Screen-Shot-2018-03-05-at-12.10.56-PM-wpcf_400x318.png

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 2.0 AMA PRA Category 1 Credit(s)™
Activity Dates: February 28, 2018 - February 27, 2019

 

Program Overview

The content for this activity is derived from a live symposium titled, “The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will focus on the role of lipoprotein(a) and its therapeutic options for patients with cardiovascular disease. A review of the science of Lp(a) and its role in the management and prevention of cardiovascular risk will be discussed. The expert faculty will examine clinical trial data and mechanisms of action of emerging therapeutics to reduce Lp(a). Information regarding how to apply emerging science into individualized treatment strategies to optimally manage Lp(a) and improve cardiovascular outcomes will be reviewed. The educational material of this symposium will provide crucial information for cardiologist to improve outcomes in patients with cardiovascular disease.

Target Audience

Cardiologists, primary care physicians, and other healthcare professionals who practice preventive cardiology.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

1. Review the science of Lp(a) and its role in the management and prevention of cardiovascular risk.
2. Examine clinical trial data and mechanisms of action of emerging therapeutics to reduce Lp(a).
3. Apply emerging science into individualized treatment strategies to optimally manage Lp(a) and improve cardiovascular outcomes.

Faculty

MoriartyPatrick M. Moriarty, MD
Professor of Medicine
Director of Clinical Pharmacology and
The Atherosclerosis/Lipoprotein-apheresis Center
University of Kansas

 

 

—-
fazio headshotSergio Fazio, MD, PhD
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University

 

MLKHeadshot 400px600p

Marlys L. Koschinsky, PhD
Scientific & Executive Director
Robarts Research Institute
Professor, Dept. of Physiology & Pharmacology
Schulich School of Medicine & Dentistry
University of Western Ontario

 

 

noorgestard

Borge G. Nordestgaard, MD, DMSc
Professor, University of Copenhagen
Chief Physician, Dept. Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital

 

thanassoulis_georgeGeorge Thanassoulis, MD, MSc
Director, Preventive and Genomic Cardiology
FRQ-S Clinician-Scientist/Chercheur-Boursier Clinicien
Associate Professor of Medicine, McGill University
McGill University Health Center

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Patrick Moriarty, MD Consultant/Advisor: Alexion; Duke; Eliaz Therapeutics; Esperion; Ionis; Kaneka; Sanofi RegeneronGrant/Research Support: Amgen; Catabasis; Ionis; Kaneka; Novartis; Regeneron; Sanofi; Stage 2 Innovations; Pfizer Inc.Speaker’s Bureau: Alexion; Kowa; Regeneron; Sanofi Regeneron
Sergio Fazio, MD, PhD Consultant/Advisor: Akcea; Amarin; Amgen; Kowa; Merck & co., Inc.; Pfizer Inc.
Marlys L. Koschinsky, PhD  Consultant/Advisor: Amgen; Eli Lily & CompanyGrant/Research Support: Eli Lily & Company; Ionis; Sanofi RegeneronSpeaker’s Bureau: Amgen; Sanofi Regeneron
Børge G. Nordestgaard, MD, DMSc   Consultant/Advisor: Aegerion; Amgen; AstraZeneca; Denka Seiken; Dezima; Ionis; Kowa; Regeneron; Sanofi RegeneronGrant/Research Support: <insert copy>Speaker’s Bureau: <insert copy>
George Thanassoulis, MD   Consultant/Advisor: Amgen; Ionis Pharmaceuticals; Servier CanadaGrant/Research Support: Ionis Pharmaceuticals; Servier CanadaSpeaker’s Bureau: Sanofi Regeneron; Servier Canada

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski and  Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.; Akcea Therapeutics and Kaneka.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc.; Akcea Therapeutics and Kaneka do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by AcademicCME-web